121 related articles for article (PubMed ID: 38892097)
1. Comparing the HER2 Status of the Primary Tumor to That of Disseminated Tumor Cells in Early Breast Cancer.
Volmer LL; Dannehl D; Matovina S; Taran FA; Walter CB; Wallwiener M; Brucker SY; Hartkopf AD; Engler T
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892097
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients.
Rack B; Zombirt E; Trapp E; Jückstock J; Andergassen U; Neugebauer J; Kost B; Weissenbacher T; Jeschke U; Schindlbeck C; Janni W; Alunni-Fabbroni M
Oncology; 2016; 90(4):232-8. PubMed ID: 26937631
[TBL] [Abstract][Full Text] [Related]
3. Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.
Krishnamurthy S; Bischoff F; Ann Mayer J; Wong K; Pham T; Kuerer H; Lodhi A; Bhattacharyya A; Hall C; Lucci A
Cancer Med; 2013 Apr; 2(2):226-33. PubMed ID: 23634290
[TBL] [Abstract][Full Text] [Related]
4. HER2-positive DTCs/CTCs in breast cancer.
Hartkopf AD; Banys M; Fehm T
Recent Results Cancer Res; 2012; 195():203-15. PubMed ID: 22527508
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S; Cristofanilli M; Singh B; Reuben J; Gao H; Cohen EN; Andreopoulou E; Hall CS; Lodhi A; Jackson S; Lucci A
Cancer; 2010 Jul; 116(14):3330-7. PubMed ID: 20564098
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
Qi G; Zhang X; Gai X; Yan X
PeerJ; 2024; 12():e17377. PubMed ID: 38766488
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and Predictive Value of Circulating and Disseminated Tumor Cells in Breast Cancer: A National Cancer Database (NCDB) Analysis.
Bilani N; Elson L; Liang H; Elimimian EB; Arteta-Bulos R; Nahleh Z
Technol Cancer Res Treat; 2020; 19():1533033820980107. PubMed ID: 33287661
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Wang C; Mu Z; Ye Z; Zhang Z; Abu-Khalaf MM; Silver DP; Palazzo JP; Jagannathan G; Fellin FM; Bhattacharya S; Jaslow RJ; Tsangaris TN; Berger A; Neupane M; Cescon TP; Lopez A; Yao K; Chong W; Lu B; Myers RE; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2020 Jun; 181(3):679-689. PubMed ID: 32367460
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
[TBL] [Abstract][Full Text] [Related]
11. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
[TBL] [Abstract][Full Text] [Related]
12. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.
Stefanovic S; Deutsch TM; Riethdorf S; Fischer C; Hartkopf A; Sinn P; Feisst M; Pantel K; Golatta M; Brucker SY; Sütterlin M; Schneeweiss A; Wallwiener M
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245182
[TBL] [Abstract][Full Text] [Related]
13. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
14. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
[TBL] [Abstract][Full Text] [Related]
15. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
16. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
17. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
Giuliano M; Herrera S; Christiny P; Shaw C; Creighton CJ; Mitchell T; Bhat R; Zhang X; Mao S; Dobrolecki LE; Al-rawi A; Chen F; Veneziani BM; Zhang XH; Hilsenbeck SG; Contreras A; Gutierrez C; Jeselsohn RM; Rimawi MF; Osborne CK; Lewis MT; Schiff R; Trivedi MV
Breast Cancer Res; 2015 Jan; 17(1):3. PubMed ID: 25572662
[TBL] [Abstract][Full Text] [Related]
18. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
[TBL] [Abstract][Full Text] [Related]
19. Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing.
Demeulemeester J; Kumar P; Møller EK; Nord S; Wedge DC; Peterson A; Mathiesen RR; Fjelldal R; Zamani Esteki M; Theunis K; Fernandez Gallardo E; Grundstad AJ; Borgen E; Baumbusch LO; Børresen-Dale AL; White KP; Kristensen VN; Van Loo P; Voet T; Naume B
Genome Biol; 2016 Dec; 17(1):250. PubMed ID: 27931250
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
